Most significantly, since overexpression of TAZ is found in over 60% lung cancer [8, 9], inhibiting TAZ or ALDH1A1 alone or in combination may provide a more effective therapy for the treatment of TAZ-associated lung cancer in the future. The gene discussed is ALDH1A1; the disease is lung carcinoma.